A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: Possible relation with prolactin secretion

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3597-3599

  Lissoni, Paolo ^a   Vigano, P ^a   Vaghi, M ^a   Frontini, L ^a   Giuberti, C ^a   Manganini, V ^a   Casu, M ^a   Brivio, F ^a   Niespolo, R ^a   Strada, G ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Hormone resistance; Prostate cancer; Tamoxifen

Indexed keywords

ANTIANDROGEN; CANCER GROWTH FACTOR; CHROMOGRANIN A; GONADORELIN DERIVATIVE; PROLACTIN; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER PAIN; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ESTROGEN ACTIVITY; GYNECOMASTIA; HORMONE RESISTANCE; HUMAN; HYPERPROLACTINEMIA; MALE; METASTASIS; NEUROSECRETORY CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROLACTIN RELEASE; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PROLACTIN; PROSTATIC NEOPLASMS; TAMOXIFEN;

EID: 23344437327     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Berruti A, Dogliotti L, Mosca A et al: Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 88: 2590-2597, 2000.
2. Berruti A, Dogliotti L, Mosca A et al: Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients. Prostate 47: 205-211, 2001.
3. Costello L and Franklin R: Effect of prolactin on the prostate. Prostate 24: 162-166, 1994.
4. Cussenot O: Growth factors and prostatic tumors. Ann Endocrinol 58: 370-380, 1997.
5. Lissoni P, Mandalà M, Giani L et al: Efficacy of bromocriptine in the treatment of metastatic breast cancer and prostate cancer-related hyperprolactinemia. Neuro-endocrinol Lett 21: 405-408, 2000.
6. Kauffman RF and Bryant HU: Selective estrogen receptor modulators. Drug News Perspect 8: 531-539, 1995.
7. waf1/cip1 Prostate 37: 51-59, 1998.
8. Yi Kim I, Seong DH, Kim BC et al: Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Res 62: 3649-3653, 2002.
9. Bonkhoff H, Fixemer T, Hunsicker I et al: Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Ann J Pathol 155: 641-647, 1999.